GermanyThe European Commission has approved Wegovy in tablet form, offering a new option for weight management that does not require injections. This development could benefit individuals who experience anxiety around needles. Wegovy contains semaglutid, a substance that mimics the gut hormone GLP-1, reducing hunger and enhancing satiety. Studies indicate that adults with obesity or overweight who take oral semaglutid can reduce their body weight by approximately 14% after 64 weeks, compared to up to 19% with the injectable version over 72 weeks. The effectiveness of both forms depends on additional measures such as calorie reduction and increased physical activity. Side effects like gastrointestinal issues are similar between the two forms, but the tablet requires strict adherence to specific intake rules—taken on an empty stomach in the morning with minimal water, followed by a 30-minute period without food, drink, or other medications. These requirements ensure the drug remains effective, as semaglutid needs protection from digestive enzymes and stomach acid.
Bias read (Center): The article discusses a medical advancement related to weight loss medication and focuses on health implications rather than political issues. It provides balanced information on the efficacy, usage, and side effects of Wegovy in tablet form, citing expert opinions and study data without apparent sl
